ArticleFrontiers in pharmacology2022

An exploratory, open-label, randomized, multicenter trial of hachimijiogan for mild Alzheimer's disease.

Mosaburo Kainuma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.